Aurobindo Pharma Limited has informed the Exchange about General Updates
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma, has received marketing authorization from the European Commission for Dazublys™, its trastuzumab biosimilar (used in breast cancer treatment). This follows a positive opinion from the EMA's CHMP in April 2025. Dazublys™ is CuraTeQ's third biosimilar approved by the EMA this year, following Dyrupeg™ (April 2025) and Zefylti™ (February 2025), and its fourth overall approval in the EU region alongside Bevqolva™, which was approved by the UK's MHRA in December 2024.
This approval expands Aurobindo's biosimilar footprint in the lucrative European market. A steady stream of biosimilar approvals signals strong R&D execution and could contribute meaningfully to long-term revenue growth, though near-term financial impact is not quantified in this filing.